Myovant Sciences Ltd

NYSE:MYOV   3:59:53 PM EDT
10.11
+0.35 (+3.59%)
Products

Myovant Sciences And Accord Healthcare, Ltd. Enter Into Exclusive License Agreement To Commercialize Orgovyx® For Advanced Hormone-Sensitive Prostate Cancer In Europe

Published: 05/09/2022 13:45 GMT
Myovant Sciences Ltd (MYOV) - Myovant Sciences and Accord Healthcare, Ltd.
Enter Into Exclusive License Agreement to Commercialize Orgovyx® for Advanced Hormone-sensitive Prostate Cancer in Europe.
Myovant Sciences Ltd - Myovant to Receive an Upfront Payment of $50 Million.
Myovant Sciences Ltd - Yovant Also Eligible to Receive Tiered Royalties From High-teens to Mid-twenties on Net Sales.
Myovant Sciences Ltd - Eligible to Receive Commercial Launch, Sales-based and Other Milestones Totaling Up to $90.5 Million.